Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
For regulators and payers, interdependence-aware attribution offers a complementary tool for evaluating RWE-based claims
Following her Master's degree, Sanchari went on to study a Ph.D
Understanding these potential interactions helps optimize therapeutic outcomes and minimize adverse effects
using a nationwide commercial administrative claims database between 2005 and 2021, the use of GLP-1 RAs in patients with T2DM, as compared to that of dipeptidyl peptidase IV (DPP-IV) inhibitors (gliptins), has not been shown to be associated with an increased risk of pulmonary complications after EGD [26]
US$ 27.37
US$ 26.86
US$ 25.68
US$ 20.03
US$ 29.49
US$ 23.79
US$ 21.54
US$ 22.45
US$ 23.09
